Combination toceranib and lomustine shows frequent high grade toxicities when used for treatment of non-resectable or recurrent mast cell tumours in dogs: A European multicentre study
| Autor: | David Argyle, S. Murphy, Paolo Buracco, Spela Bavcar, P. De Fornel, Michael Kessler, Johannes Hirschberger, J. P. de Vos |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2017 |
| Předmět: |
medicine.medical_specialty
Poor prognosis Indoles Skin Neoplasms Toceranib 040301 veterinary sciences Prednisolone Mast cell tumour Canine 0403 veterinary science 03 medical and health sciences Dogs 0302 clinical medicine Lomustine Antineoplastic Combined Chemotherapy Protocols Canine Mast cell tumour Toceranib Palladia Lomustine Adverse events Animals Medicine Pyrroles Dog Diseases Mast Cells Prospective Studies Prospective cohort study Adverse effect Antineoplastic Agents Alkylating Objective response General Veterinary Palladia business.industry Receptor Protein-Tyrosine Kinases 04 agricultural and veterinary sciences Mast cell Surgery Europe medicine.anatomical_structure 030220 oncology & carcinogenesis Adverse events Animal Science and Zoology Neoplasm Recurrence Local business medicine.drug |
| Zdroj: | Bavcar, S, De Vos, J, Kessler, M, De Fornel, P, Buracco, P, Murphy, S, Hirschberger, J & Argyle, D 2017, ' Combination toceranib and lomustine shows frequent high grade toxicities when used for treatment of non-resectable or recurrent mast cell tumours in dogs: A European multicentre study ', The Veterinary Journal, vol. 224, pp. 1-6 . https://doi.org/10.1016/j.tvjl.2017.04.010 |
| Popis: | Mast cell tumours (MCTs) in dogs can present in a variety of forms. Non-resectable, recurrent or metastatic MCTs usually carry a poor prognosis and present a therapeutic challenge. Both toceranib and lomustine have shown single agent activity against MCTs in dogs. In this study, 10 dogs with advanced MCTs were enrolled prospectively and treated with toceranib (median dose 2.7 mg/kg orally every other day), lomustine (median dose 60 mg/m2 orally every 3 weeks) and prednisolone (1 mg/kg orally every other day, alternating with toceranib). Severe adverse events (SAEs), requiring alterations in the protocol, occurred in all dogs. The objective response rate was 50%. Three dogs died or were euthanased due to SAEs and therefore enrolment of new dogs was discontinued prematurely. A long term response (> 1 year) was observed in two dogs. Modifications of the protocol are required for future prospective studies. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|